Canada’s particle physics laboratory TRIUMF is making a push to be a future world leader in the production of a special radioactive isotope nicknamed the “rarest drug on Earth,” which can deliver devastating amounts of energy to single cancer cells, without harming nearby tissue. Read the article here.
Daily image-guided radiotherapy (IGRT) may reduce the rate of late rectal toxicity vs weekly therapy, according to research being presented at the 2018 Genitourinary Cancers Symposium in San Francisco, California. Daily IGRT was, however, also associated with a greater risk of secondary cancers and worse overall survival (OS). Read the article here.
A study by researchers at the UCLA Jonsson Comprehensive Cancer Center provides convincing evidence that radiation-based treatments and surgery are equally effective treatments for aggressive prostate cancer. It also suggests that a particular form of radiation therapy, consisting of external radiation followed by brachytherapy (a type of radiation treatment in which a radioactive source is placed into the tumor directly) provides the best chance of preventing metastatic disease. Read the article here.
A “game changer” study has concluded many prostate cancer patients need half as much radiation treatment as currently given. Ontario hospitals are already starting to change treatment to four weeks from the standard eight because of the study led by Hamilton’s Juravinski and Toronto’s Princess Margaret cancer centres. Read the article here.